Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zinterol SCHEMBL14452736 | 1.00 | ADRB2 (1.00) | ADRB2ADRB3 | |
| Zinterol SCHEMBL30338438 | 1.00 | ADRB2 (1.00) | ADRB2ADRB3 | |
| Zinterol SCHEMBL29390397 | 0.99 | ADRB2 (1.00) | ADRB2ADRB3 | |
| Zinterol SCHEMBL637070 | 0.99 | ADRB2 (1.00) | ADRB2ADRB3 | |
| Zinterol SCHEMBL1551570 | 0.92 | ADRB2 (0.85) | ADRB2ADRB3 | |
| Zinterol SCHEMBL11796024 | 0.92 | ADRB2 (0.85) | ADRB2ADRB3 | |
| SCHEMBL14451873 | 0.89 | ADRB2 (0.81) | ADRB2ADRB3 | |
| SCHEMBL14620429 | 0.89 | ADRB2 (0.80) | ADRB2ADRB3 | |
| SCHEMBL12305639 | 0.89 | ADRB2 (0.80) | ADRB2ADRB3 | |
| SCHEMBL2450164 | 0.88 | ADRB2 (0.79) | ADRB2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398729-A1 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | US | claimed |
| EP-4329849-A1 | INHALER | 3D Engineering Design Limited (GB) | 2024-03-06 | — | — | EP | claimed |
| US-20230158028-A1 | COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-25 | — | — | US | claimed |
| EP-4132914-A1 | COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION | The Regents of the University of California (US) | 2023-02-15 | — | — | EP | claimed |
| WO-2022229665-A1 | INHALER | 3D Engineering Design Limited (GB) | 2022-11-03 | — | — | WO | claimed |
| EP-3946268-A1 | INHALED STATINS AS BRONCHODILATORS TO IMPROVE LUNG FUNCTION IN RESPIRATORY DISEASES | The Regents of The University of California (US) | 2022-02-09 | — | — | EP | claimed |
| US-20220034911-A1 | METHOD OF MITIGATION OF DEATH FROM EPILEPTIC SEIZURES | VEGA JOSE (US) | 2022-02-03 | — | — | US | claimed |
| US-20210338603-A1 | COMBINATIONS OF ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES | ATROGI AB (SE) | 2021-11-04 | — | — | US | claimed |
| US-20200315993-A1 | COMBINATIONS OF ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES | ATROGI AB (SE) | 2020-10-08 | — | — | US | claimed |
| WO-2020205663-A1 | INHALED STATINS AS BRONCHODILATORS TO IMPROVE LUNG FUNCTION IN RESPIRATORY DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-08 | — | — | WO | claimed |
| WO-2006108424-A2 | BETA-2 ADRENOCEPTOR AGONISTS FOR TREATING CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION PHARMA A/S (DK) | 2006-10-19 | — | — | WO | claimed |
| US-20060235048-A1 | Treatment of connective tissue diseases of the skin | ASTION DEVELOPMENT A/S | 2006-10-19 | — | — | US | claimed |
| EP-1613266-A2 | METHODS OF TREATING PAIN AND COMPOSITIONS FOR USE THEREFOR | Theraquest Biosciences, LLC (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004091540-A2 | METHODS OF TREATING PAIN AND COMPOSITIONS FOR USE THEREFOR | THERAQUEST BIOSCIENCES, LLC (US) | 2004-10-28 | — | — | WO | claimed |
| US-20040209850-A1 | synergistic mixture of an analgesic ( opioid, NSAID, COX-2 inhibitor, acetaminophen, or tramadol) and a beta adrenergic agonist; faster response and longer duration; reduced gastrointestinal side effects | THERAQUEST BIOSCIENCES, LLC | 2004-10-21 | — | — | US | claimed |
| US-6624181-B1 | Synergistic combination | ALTANA PHARMA AG (DE) | 2003-09-23 | — | — | US | claimed |
| WO-2003075851-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANORECTAL DISORDERS | CELLEGY PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-1994008579-A1 | β-AGONIST, α1-AGONIST, AND/OR α2-ANTAGONIST TREATMENT OF NEURODEGENERATIVE DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA | NEW YORK UNIVERSITY (US) | 1994-04-28 | — | — | WO | claimed |
| US-3993776-A | 2*-HYDROXY-5*-(1-HYDROXY-2-(2-METHYL-1-PHENYL-2 -PROPYLAMINO)ETHYL)METHANE-SULFONANILIDE | MEAD JOHNSON & COMPANY (US) | 1976-11-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158028-A1 | COMPOUNDS AND METHODS FOR INDUCING UCP1 EXPRESSION | TFAM, FABP4, CPT2 | ADRB2 88/4885ADRB3 83/4885 |
| US-20200315993-A1 | COMBINATIONS OF ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES | ADRB2, ADRB3, ADRA2C | ADRB2 1/4885ADRB3 2/4885 |
| US-20060235048-A1 | Treatment of connective tissue diseases of the skin | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB3 7/4885 |
| US-20210338603-A1 | COMBINATIONS OF ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES | ADRB2, ADRB3, ADRA2C | ADRB2 1/4885ADRB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.